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Smad proteins transduce transforming growth factor-b signals from the cell surface to the nucleus, regulating a variety of
physiologic processes. In the nucleus, Smads control gene expression by binding to both DNA and transcription factors.
Individual Smads regulate distinct subsets of target genes. The key residues important for this specificity are thought to
reside in the carboxyl-terminal MH2 domain. To further examine Smad specificity in vivo, we undertook structure-function
studies in Xenopus laevis embryos and found that truncated Smads containing the MH2 domain activate gene transcription.
striking finding revealed by the in vivo analyses was that the functional truncated Smads all behaved identically and had
ost wild-type specificity. For most Smads, wild-type activity required the presence of an MH1 domain, either in cis or in
rans. Of note, even heterologous MH1 domains could restore wild-type signaling specificity to effector MH2 domains. We
ound a possible mechanism to account for these observations, as Smad MH1 domains altered the binding of pathway-
pecific transcription factors to the MH2 domain. Thus, Smad MH1 domains are important to the regulation of
ranscriptional specificity. © 2001 Academic Press
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hINTRODUCTION
Specificity is a key feature of many biological processes
and its loss underlies many important disease states includ-
ing cancers, endocrinopathies, and autoimmune syndromes
(reviewed in Hata et al., 1998b; Letterio and Roberts, 1998;
Massague, 1998; Padgett, 1999). Therefore, understanding
the mechanistic basis of specificity might advance our
insight into both physiological and pathophysiological
states. Given its importance, it is not surprising that
specificity is controlled at many levels including ligand–
receptor interactions and through regulation of gene tran-
scription (Pawson and Nash, 2000; Piek et al., 1999).
Transcriptional specificity is often controlled by signal
ransduction cascades. This precise regulation is exempli-
ed by the transforming growth factor-b (TGF-b) superfam-
ily, which includes the TGF-bs, activins, and BMPs (re-
iewed in Heldin et al., 1997; Massague and Chen, 2000;
iek et al., 1999; Whitman, 1998; Wrana, 2000). These
ignaling pathways play central roles in the control of cell
rowth, differentiation, immunity, sexual identity, and
1 To whom correspondence should be addressed. Fax: (214) 648-
1960. E-mail: graff02@utsw.swmed.edu.
110evelopment (reviewed in Letterio and Roberts, 1998; Mas-
ague, 1998; Patterson and Padgett, 1999; Whitman, 1998).
GF-b superfamily signaling is conveyed from the cell
embrane to the nucleus by the Smad family of proteins
Heldin et al., 1997; Massague, 1998; ten Dijke et al., 2000).
ertebrates contain at least 10 distinct Smads, two of
hich, Smad2 and Smad4, are tumor suppressor genes in
umans (Eppert et al., 1996; Hahn et al., 1996; Hata et al.,
1997; reviewed in Heldin et al., 1997; Massague, 1998). The
Smads can be subdivided into three separate classes (Heldin
et al., 1997; Massague, 1998). The first class is the receptor-
regulated Smads (R-Smads), which are restricted to distinct
signaling pathways and contain carboxyl-terminal SSXS
phosphorylation site motifs (Heldin et al., 1997; Massague,
1998). Smad4 is the best described vertebrate member of the
second class, the co-Smads, and it associates with the
R-Smads upon signal activation (Howell et al., 1999; Lagna
et al., 1996; Masuyama et al., 1999; Zhang et al., 1997). The
third and most divergent Smads are the antagonistic Smads,
Smad6 and Smad7 (Hata et al., 1998a; Hayashi et al., 1997;
Imamura et al., 1997; Nakao et al., 1997a).
The TGF-b superfamily is a useful model system for the
study of signaling specificity because the transduction
pathway is relatively parsimonious (Massague, 1998). The
0012-1606/01 $35.00
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111Smad Transcriptional Specificitysignaling cascades begin when the ligands bind to and
activate their cognate transmembrane serine kinase recep-
tor (Heldin et al., 1997; Massague, 1998). The activated
eceptors then phosphorylate the appropriate R-Smads; ac-
ivin and TGF-b receptors phosphorylate and activate
mad2 and Smad3, while the BMP receptors activate
mad1, Smad5, and Smad8 (Chen et al., 1997b; Eppert et al.,
996; Hoodless et al., 1996; Lagna et al., 1996; Nakao et al.,
997b; Tamaki et al., 1998; Zhang et al., 1996). Then, the
hosphorylated R-Smads heteromerize with Smad4 (Hata et
l., 1997; Howell et al., 1999; Kretzschmar et al., 1997;
agna et al., 1996; Masuyama et al., 1999; Nakao et al.,
1997b; Zhang et al., 1996). After association, the R-Smad:
Smad4 complex translocates to the nucleus, where the
complex binds to both DNA and transcription factors and
alters the expression of distinct subsets of genes (Chen et
al., 1996; Chen et al., 1997a; Germain et al., 2000; Hua et
l., 1998; Labbe et al., 1998; Liberati et al., 1999; Liu et al.,
999; Moustakas and Kardassis, 1998; Zhang et al., 1998).
R- and co-Smads contain two highly conserved domains,
he amino terminal MH1 domain and the carboxyl terminal
H2 domain (Heldin et al., 1997; Massague, 1998; Piek et
al., 1999). The MH1 domain, at least in some Smads, binds
DNA. Direct DNA binding has been demonstrated for
Smad3, Smad4, and for the founding member of the family,
Drosophila Mad (Dennler et al., 1998; Kim et al., 1997; Shi
et al., 1998; Yingling et al., 1997; Zawel et al., 1998). The
MH1 domain is also thought to inhibit the function of the
MH2 effector domain, at least for Smad2, Smad3, and
Smad4 (Baker and Harland, 1996; Hata et al., 1997; Liu et
al., 1996; Wu et al., 1997). The MH2 domain also has
several identifiable functions. First, the MH2 domain con-
tains residues critical for homo- and hetero-oligomerization
(Hata et al., 1998a, 1997; Lagna et al., 1996; Wu et al., 1997;
Zhang et al., 1997). Second, the MH2 contains the transac-
tivation domain and the isolated MH2 domain can activate
gene expression (Baker and Harland, 1996; Liu et al., 1996,
1997; Wu et al., 1997). Third, the MH2 domain is thought to
possess the identical transcriptional specificity as the wild-
type parent Smad (Baker and Harland, 1996; Meersseman et
al., 1997). For example, in Xenopus mesoderm induction
assays, the Smad2 MH2 domain induced a full range of
activin responses that mimicked the effects of the full-
length Smad2 (Baker and Harland, 1996). Consistent with
that idea, the MH2 contains residues essential both for
appropriate transcriptional specificity and for interaction
with sequence-specific transcription factors (Chen et al.,
1997a, 1998; Lagna and Hemmati-Brivanlou, 1999; Liberati
et al., 1999; Zhang et al., 1998).
One especially notable feature of the TGF-b superfamily
nd the Smads is that they transduce distinct and specific
ignals (Chen et al., 1998; Graff et al., 1996; Heldin et al.,
997; Hoodless et al., 1996; Lagna and Hemmati-Brivanlou,
999; LeSueur and Graff, 1999; Liu et al., 1996; Suzuki et
l., 1997). This specificity has been demonstrated in both
iochemical and in vivo experiments and both produced
quivalent results (Eppert et al., 1996; Graff et al., 1996;
Copyright © 2001 by Academic Press. All rightoodless et al., 1996; LeSueur and Graff, 1999). For ex-
mple, biochemical studies show that Smad1 and Smad5
unction downstream of BMP and the BMP receptor (Hood-
ess et al., 1996; Kretzschmar et al., 1997; Macias-Silva et
al., 1998; Tamaki et al., 1998). Activation of BMP signaling
leads to the phosphorylation and nuclear translocation of
Smad1 and Smad5 but not of Smad2 and Smad3
(Kretzschmar et al., 1997; Macias-Silva et al., 1998; Tamaki
et al., 1998). In concert with that, BMP, the activated BMP
receptor, Smad1, and Smad5 all induce the expression of
blood in Xenopus embryos while activin, TGF-b, their
activated receptors, and Smad2 do not (Graff et al., 1996;
Hemmati-Brivanlou and Thomsen, 1995; Liu et al., 1996;
Suzuki et al., 1997; Thomsen, 1996; Zhang et al., 1997).
Similar results hold for Smad2, which functions down-
stream of activin and TGF-b in biochemical experiments
nd induces formation of muscle in Xenopus, phenocopying
he effects of activin (Baker and Harland, 1996; Eppert et al.,
996; Graff et al., 1996; Macias-Silva et al., 1996; Nakao et
al., 1997b,c). Previous studies have demonstrated that the
distinct in vivo responses seen with BMP and activin
signaling are not concentration-dependent differences. For
example, no dose of Smad2 leads to expression of the
ventral marker globin and similarly, no dose of Smad1
induces expression of the dorsal markers goosecoid, actin,
or NCAM. This precision is based, at least in part, upon the
interaction with sequence-specific transcription factors
such as FAST-1 (Chen et al., 1996, 1997a; Germain et al.,
2000; Watanabe and Whitman, 1999; Zhou et al., 1998).
As a step toward understanding the specificity of Smad
action, we undertook structure-function studies and ex-
ploited the unique advantages provided by in vivo analysis
in Xenopus. Frog embryos are an excellent choice for these
experiments as they have several discrete readouts for Smad
function (Baker and Harland, 1996; Graff et al., 1996; Lagna
et al., 1996; Liu et al., 1996; Suzuki et al., 1997). In animal
cap explants, Smad1 and Smad5 induce the expression of
globin (blood); Smad2 induces the expression of muscle
actin (muscle); Smad10 induces the expression of NCAM
(neural); and a new Smad, Smad11, has no activity that we
have yet detected (Baker and Harland, 1996; Graff et al.,
1996; LeSueur and Graff, 1999; Suzuki et al., 1997). In this
report, we found that truncated forms of these Smads (1, 2,
5, 10, and 11) that contained the effector MH2 domain all
induced expression of muscle actin. That is, the various
truncations had equivalent function, and, except for Smad2,
had lost wild-type specificity. Addition of an MH1 domain,
either in cis or in trans, restored wild-type specificity to the
MH2 domain. Of note, the MH1 domains that rescued
wild-type specificity to the MH2 domain could be derived
from Smads other than that of the MH2 parent. Yet, the
function detected was still that of the parent of the MH2
domain. One possible explanation for the requirement of an
MH1 domain for wild-type function was that the MH1
domain might alter the interaction of the MH2 domain
with sequence-specific transcription factors such as
FAST-1. Biochemical studies were consistent with that
s of reproduction in any form reserved.
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112 Fortuno, LeSueur, and Graffidea; wild-type Smad1 did not interact with FAST-1, while
the isolated Smad1 MH2 domain did. Taken together, these
data suggest that the MH1 domain permits wild-type speci-
ficity by altering the choice of transcriptional partners and,
hence, downstream targets.
MATERIALS AND METHODS
Constructs
The Smad and FAST-1 clones were generated in a 50-ml reaction
hat contained 13 Thermopol buffer, 1.6 mM dNTPs, 1 U Vent
olymerase, 100–500 ng of template DNA, and the appropriate
ligonucleotide primers containing restriction site linkers to facili-
ate cloning. The reaction mixture was incubated at 94°C for 3
in, followed by 20 cycles of 94°C for 1 min, 55°C for 1 min, and
2°C for 2 min, and then a final 5 min at 72°C. For the truncations,Copyright © 2001 by Academic Press. All rightosition. To create the chimeric constructs, SOEing was performed
s described by Pease and colleagues (Horton et al., 1989). The PCR
roducts were digested with the appropriate restriction enzymes,
solated on agarose gels, and ligated into p64TNE, pCS21, or
pCS105 (gifts of Ali Hemmati-Brivanlou, David Turner, and
Richard Harland). The myc-tagged constructs were generated by
ligating the fragments into pCS31MT (a generous gift of David
Turner). For the yeast two-hybrid assays, FAST-1 was cloned
into the bait vector pBTM116 while the Smad constructs were
inserted into pACT2 (Clontech) containing the Gal4 activation
domain. Smad4 and Smad5 were generous gifts of Drs. Joan
Massague and Ali Hemmati-Brivanlou (Lagna et al., 1996; Su-
zuki et al., 1997). Malcolm Whitman generously provided myc-
Smad1, myc-Smad2, GST-FAST-1, and DN-FAST-1 (Chen et al.,
1996, 1997a; Watanabe and Whitman, 1999). All clones were
sequenced for verification.
The constructs, primer sequences, vectors, and the restriction
enzymes used to linearize templates for in vitro transcription aren exogenous start methionine was engineered at the appropriate listed below.
Constructs Primer sequence Vector Linearized
mad2 GCAGATCTATGTCGTCCATCTTGCCT p64TNE BglII-EcoRI XbaI
CGGAATTCTTAGGACATGCTTGAGCAGC
mad2LDE GCAGATCTCCATGTTAGACGAGCTTGAGGCG pCS2 BamHI/EcoRI NotI
CGGAATTATTAGGACATGCTTGAGCAGC
mad2RSL GCAGATCTCCATGAGGTCTCTTGATGGTCGAC pCS2 BamHI/EcoRI NotI
CGGAATTATTAGGACATGCTTGAGCAGC
Smad2ILT GAAGATCTCCATGATCTTGACAGAGCTGCCAG p64TNE BglII-EcoRI XbaI
CGGAATTATTAGGACATGCTTGAGCAGC
Smad2ETP GAAGATCTCCATGGAAACACCACCTCCTGGA p64TNE BglII-EcoRI XbaI
CGGAATTATTAGGACATGCTTGAGCAGC
Smad1 CGGGATCCATGAATGTGACGAGCTTG p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1QGD GAAGATCTCCATGCAGGGAGACGAAGAAGAG p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1MEE GAAGATCTCCATGGAGGAACTGGAAAAGGCC pCS2 BamHI-EcoRI NotI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1RSL GAAGATCTCCATGCGTTCCTTGGATGGCAGG p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1YNP GAAGATCTCCATGTACAACCCACAGCACAG p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1MPH GAAGATCTCCATGCCTCACAACGCAACTTTTCC p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1YPN GAAGATCTCCATGTACCCAAACTCTCCGGGAAG p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1DTP GCGGATCCATGGACACCCCTCCTCCAGCT p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1VAY GAAGATCTCCATGGTTGCATATGAAGAGCC p64TNE BglII-EcoRI XbaI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad10 CGGGATCCATGGCGTTTGCCAGCCTAG pCS2 BamHI-EcoRI XbaI
CGGAATTCTTAGTTGACAGAACTGGG
Smad11 CGGGATCCATGCACGCCAGCACTCCC p64TNE BglII-EcoRI XbaI
CGGAATTCTTACGATACGGCAGAGATTGG
Smad4TWT CGGGATCCCCATGACCTGGACTGGAAGTAGG pCS2 BamHI-EcoRI NotI
CGGAATTCTCAGTCTAAAGGTTGTGGGTC
Smad5DTP GAAGATCTCCATGGACACCCCTCCCCCTGC p64TNE BglII XbaI
GAAGATCTCTATGAAACAGAAGAAATGGG
Smad10SWT GCGGATCCATGTCTTGGACAGGGAGCAGC p64TNE BglII-EcoRI XbaI
CGGAATTCTTAGTTGACAGAACTGGGs of reproduction in any form reserved.
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113Smad Transcriptional SpecificityConstructs Primer sequence Vector Linearized
mad11ETP GCGGATCCATGGAGACGCCCCCTCCGCCA p64TNE BglII-EcoRI XbaI
CGGAATTCTTACGATACGGCAGAGATTGG
mad2/10 GCAGATCTATGTCGTCCATCTTGCCT p64TNE BglII XbaI
CCCTGTCCAAGATGGAATATAATTGCTCTG
AATTATATTCCATCTTGGACAGGGAGCAGC
CGGAATTCTTAGTTGACAGAACTGGG
mad10/2 CGGAATTCCCATGGCGTTTGCCAGCCTAG pCS2 EcoRI NotI
AGGTGGTGTTTCAGCATGGAAAGGCTGCCT
CCTTCCCATGCTGAAACACCACCTCCTGG
CGGAATTATTAGGACATGCTTGAGCAGC
mad1/10 CGGGATCCATGAATGTGACGAGCTTG p64TNE BglII-EcoRI XbaI
AACGGAGCACCAGTGTTTTGGCTCTTCATATGC
GAGCCAAAACACTGGTGCTCCGTTGCCTATTTC
CGGAATTCTTAGTTGACAGAACTGGG
mad10/1 CGGGATCCATGGCGTTTGCCAGCCTAG p64TNE BglII-EcoRI XbaI
AATGGAGCACCAGAACTCTGGGCCTGGGTG
GGCCCAGAGTTCTGGTGCTCCATTGTCTATTATG
CGGAATTCTTAAGAGACCGAGGAGATGGG
mad5/2 GAGCGGCCGCCCATGACGTCAATGGCCAGC p64TNE NotI XbaI
TATAGAGCACCAGTGTTTGGGCTCCTCATA
GAGCCCAAACACTGGTGCTCTATAGCATAC
GAGCGGCCGCCCTTAGGACATGCTTGAGCAGCG
Smad2/5 GCAGATCTATGTCGTCCATCTTGCCT pCS2 BamHI NotI
GGGAGGGGTGTCTGGAATATAATTGCTCTG
AATTATATTCCAGACACCCCTCCCCCTGCC
GAAGATCTCTATGAAACAGAAGAAATGGG
Smad1/2 GAAGATCTATGCCATGAATGTGACGAGCTTG p64TNE BglII-EcoRI XbaI
TTCACTAATATACCCGGGAGGAGGGGTGTCAGCTGG
ACCCCTCCTCCCGGGTATATTAGTGAAGATGG
CGGAATTATTAGGACATGCTTGAGCAGC
Smad2/1 GCAGATCTATGTCGTCCATCTTGCCT p64TNE BglII-EcoRI XbaI
AGGAGGGGTGTCTGGAATATAATTGCTCTG
AATTATATTCCAGACACCCCTCCTCCAGCT
CGGAATTCTTAAGAGACCGAGGAGATGGG
Smad1N CGGGATCCATGAATGTGACGAGCTTG pCS2 BamHI-EcoRI NotI
CGGAATTCTTAAGCTGGTATTTGAAAAGG
Smad2N GCAGATCTATGTCGTCCATCTTGCCT pCS105 BamHI-EcoRI NotI
CGGAATTCTTATGGAATATAATTGCTCTG
Smad10N CGGGATCCATGGCGTTTGCCAGCCTAG pCS2 BamHI-EcoRI NotI
CGGAATTCTTAAGCATGGAAAGGCTGCTTTGG
myc-Smad1DTP GAAGATCTCCATGGACACCCCTCCTCCAGCT pCS3MT BglII-EcoRI NotI
CGGAATTCTTAAGAGACCGAGGAGATGGG
myc-Smad2ETP GAAGATCTCCATGGAAACACCACCTCCTGGA pCS3MT BglII-EcoRI NotI
CGGAATTATTAGGACATGCTTGAGCAGC
Gal4 DB FAST-1 GAAGATCTTGATGAGAGACCCCTCCAGTC pBTM116 BamHI
CGAGATCTCTACATAAGGCCTTGTCT
Gal4 AD Smad1 GAAGATCTCCATGAATGTGACGAGCTTG pACT2 BamHI-EcoRI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Gal4 AD Smad1DTP GAAGATCTCGATGAATGTGACGAGCTTG pACT2 BamHI-EcoRI
CGGAATTCTTAAGAGACCGAGGAGATGGG
Gal4 AD Smad5 GAAGATCTCCATGACGTCAATGGCCAGC pACT2 BamHI
GAAGATCTCTATGAAACAGAAGAAATGGG
Gal4 AD Smad5DTP GAAGATCTCCATGGACACCCCTCCCCCTGC pACT2 BamHI
GAAGATCTCTATGAAACAGAAGAAATGGG
Gal4 AD Smad2 GAAGATCTCGATGTCGTCCATCTTGCCT pACT2 BamHI-EcoRI
CGGAATTATTAGGACATGCTTGAGCAGC
Gal4 AD Smad2ETP GAAGATCTCCATGGAAACACCACCTCCTGGA pACT2 BamHI-EcoRI
CGGAATTATTAGGACATGCTTGAGCAGCCopyright © 2001 by Academic Press. All rights of reproduction in any form reserved.
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114 Fortuno, LeSueur, and GraffIn Vitro Transcription, Animal Cap Assay,
and RT-PCR
Synthetic, capped mRNA for animal cap experiments was
generated from linearized plasmid templates with the SP6
polymerase as described (Krieg and Melton, 1987). Embryos were
staged according to Nieuwkoop and Faber (1967). The animal
cap assays were done as described (Graff et al., 1994; Thomsen
and Melton, 1993). In brief, one-cell stage Xenopus embryosD: ACTGCCTTGATGACTCCTA
the relative strength of binding between the Smads and FAST-1, a
t
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a
m
a
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Copyright © 2001 by Academic Press. All rightdescribed in the figure legends. Animal caps were explanted
at the blastula stage, cultured to stage 27 or 28, and then total
RNA was harvested. RNA was extracted and analyzed by RT-
PCR as described (Graff et al., 1994; Wilson and Melton, 1994).
In each experiment, the amplified products were derived from
total RNA isolated from a pool of five animal caps. All animal
cap assays were performed at least three times. The conditions
for the PCR detection of the molecular markers and the primerwere either uninjected (control) or injected with mRNA as sequences have been described:
Marker Sequences Reference
Globin U: GCCTACAACCTGAGAGTGG Graff et al., 1994
D: CAGGCTGGTGAGCTGCCC
Muscle actin U: GCTGACAGAAATGCAGAAG Wilson and Melton, 1994
D: TTGCTTGGAGGAGTGTGT
NCAM U: CACAGTTCCAACCAAATGC Hemmati-Brivanlou and Melton, 1994
D: GGAATCAAGCGGTACAGA
EF-1a U: CAGATTGGTGCTGGATATGC Krieg et al., 1989
GGST Pull-Down Assays
Myc-tagged Smad constructs were microinjected into one-cell
stage Xenopus embryos with or without GST-FAST-1. At stage 8.5,
15 embryos were lysed in 250 ml of lysate buffer (50 mM Tris–HCl
pH 8, 25% glycerol, 50 mM KCl, 2 mM DTT, 0.5 mM phenylmeth-
ylsulfonyl fluoride, 1 mM EDTA, 1 mM EGTA, 25 mg/ml leupep-
in, 25 mg/ml a-macroglobulin, 25 mg/ml SBTI, 25 mM
b-glycerolphosphate, and 2 mM sodium vanadate) and the lysate
was centrifuged for 20 min at 15,000g, 4°C. GST-FAST-1 was
precipitated at 4°C for 1 h with 50 ml of a 1:1 slurry of glutathione
eads. Prior to the pull-down assay, the beads were blocked for 2 h
t 4°C with precleared lysates from uninjected blastula embryos.
fter the glutathione beads were incubated with the lysates, they
ere pelleted and serially washed in 13 lysate buffer, 0.2 M NaCl,
nd 0.25% NP-40; 13 lysate buffer, 0.4 M NaCl; 13 lysate buffer,
.5% NP-40; 13 lysate buffer, 0.2 M NaCl, and 0.25% NP-40; and
nally with 13 lysate buffer. After boiling in sample buffer, the
roteins were separated with SDS–PAGE and myc-Smad proteins
hat bound to FAST-1 were detected by Western blotting with
E10. A similar protocol was designed to assess the effect of the
mad MH1 domain on the association of the Smad MH2 domain
ith FAST-1, except that oocytes were injected and harvested after
60 h.
Yeast Two-Hybrid and Liquid b-Galactosidase
Assays
The yeast two-hybrid assays were performed with standard
methods (Chien et al., 1991). In brief, 2 mg of Gal4DB-FAST-1, 2 mg
f Gal4AD-Smad plasmids, and 50 mg of carrier DNA were incu-
bated at 30°C with 50 ml of competent L40 yeast cells. After 30
min, 0.4 ml of 40% PEG-4000 was added to the transformation mix
for 1 h. Cells were pelleted, washed, resuspended, and then plated
on complete minimal plates lacking tryptophan and leucine for
selection. After 3 days at 30°C, colonies were streaked on similar
selection plates and allowed to grow for 2 more days. To measureliquid b-galactosidase assay was performed (Tall et al., 1999). For
he assay, we grew the streaked transformants overnight in 5 ml of
election media (-trp, -leu). The next day, 1 ml of this culture was
dded to 4 ml of YPD broth and cultured until the OD600 was
between 0.4 and 1.0. Then, 1.5 ml of the culture was pelleted,
washed, and resuspended in 350 ml Z buffer (60 mM
Na2HPO4 z 7H2O, 40 mM NaH2PO4 z H2O, 10 mM KCl, and 1 mM
MgSO4 z 7H2O at pH 7.0). Triplicate aliquots (100 ml) were trans-
ferred to three tubes, frozen in liquid nitrogen, and thawed at 37°C.
Next, 700 ml of Z buffer containing b-mercaptoethanol (270 ml
b-ME/100 ml Z buffer) and 160 ml of freshly prepared ONPG (4
g/ml) were added to each tube and incubated at 30°C. At
ppropriate time points, the reactions were quenched with 400 ml
of 1 M Na2CO3. For quantitation, the 420-nm absorbance was
measured and the relative b-galactosidase units were calculated as
ollows: 1000 3 OD420/(minutes 3 0.1 ml 3 4.3 3 OD600).
RESULTS
Smad MH2 Domains Lose Wild-Type Specificity
To identify and characterize domains important to Smad
function and specificity, we generated a series of Smads,
named for their first three amino acids, that were deleted
sequentially from the amino to the carboxyl terminus,
which contains the transactivation domain (Fig. 1) (Baker
and Harland, 1996; Liu et al., 1996, 1997; Wu et al., 1997).
The constructs were designed in this manner as the car-
boxyl MH2 domains have effector function. We analyzed
the biological activity of each construct by expressing them
in Xenopus animal pole explants (animal caps). Animal caps
ormally become ciliated epidermis (skin), an ectodermal
erivative, but can be converted into either dorsal meso-
erm (Smad2), ventral mesoderm (Smad1 or Smad5), or
eural tissue (Smad10) depending on which Smad is ex-
ressed (Fig. 1) (Baker and Harland, 1996; Graff et al., 1996;
s of reproduction in any form reserved.
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1996). These three tissue types are easily distinguished by
morphological, histological, and molecular criteria (Graff et
al., 1996). Dorsal mesoderm (Smad2) contains muscle and
expresses the marker muscle actin (Figs. 1A and 1C);
ventral mesoderm (Smad1) contains blood, scored by ex-
FIG. 1. Smad MH2 domains lose wild-type specificity. (A) A seri
each construct was named for the first three amino acids after t
construct was microinjected into one-cell stage Xenopus embryos a
total RNA was harvested from a pool of 5 animal caps and assay
constructs induced expression of muscle actin. Control animal cap
a loading control (Krieg et al., 1989). M. actin is a marker
(Hemmati-Brivanlou et al., 1990; Mohun et al., 1984). RNA from w
(2RT) is identical to the embryo lane except that reverse transcrip
of a series of Xenopus Smad1 truncations was analyzed in animal ca
induced the expression of globin; the next 5 truncations were inacti
exhibited the activity of wild-type Smad2 rather than Smad1. Four
doses (.10 ng) were tested for the inactive constructs but no act
demonstrated that all the Smad1 constructs were expressed to ro
placed at the analogous positions to the Smad2 constructs in (A)
equate to wild-type Smad activity. Animal caps expressing full-len
Smad4; 4 ng of each) or Smads truncated at equivalent positio
Smad4TWT [4C], 4 ng of each, except 1 ng of Smad2ETP) were ass
note, all the truncated Smads, except for the co-Smad, Smad4, were
Smad2. NCAM marks neural tissue (Kintner and Melton, 1987).pression of globin (Figs. 1B and 1C), and neural tissue
Copyright © 2001 by Academic Press. All rightSmad10) is marked by expression of NCAM (Fig. 1C). To
etermine whether the truncations were functional, syn-
hetic mRNA encoding each construct was injected into the
nimal poles of fertilized eggs and animal caps were re-
oved, cultured, and then assayed for changes in morphol-
gy and differential expression of molecular markers.
Xenopus Smad2 amino-terminal truncations were generated, and
te of truncation. Synthetic mRNA (0.1 and 1 ng) encoding each
imal caps were dissected from blastula stage embryos. At stage 27,
RT-PCR for induction of the indicated markers. All the Smad2
y expressed EF-1a, a ubiquitously expressed message that serves as
rsal mesoderm and globin is a marker of ventral mesoderm
embryos (Embryo) serves as a positive control; the negative control
was omitted and hence no cDNA was generated. (B) The function
ays. The two longest constructs, wild-type Smad1 and Smad1QGD,
hile the two shortest constructs, Smad1DTP and Smad1VAY, both
grams of synthetic mRNA was injected for each construct. Higher
was detected and Western blots with Smad1-specific antibodies
equal levels (not shown). Asterisks indicate Smad1 truncations
on sequence alignment. (C) The effector MH2 domain does not
mads (Xenopus Smads 1, 2, 10, and 11, murine Smad5 and human
Smad1DTP, Smad2ETP, Smad5DTP, Smad10SWT, Smad11ETP,
by RT-PCR for expression of the indicated molecular markers. Of
e and induced the expression of muscle actin, mimicking wild-typees of
he si
nd an
ed by
s onl
of do
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tase
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116 Fortuno, LeSueur, and GraffXenopus Smad2 (Fig. 1A), which has served as a model for
Smad function (Baker and Harland, 1996; Lagna et al., 1996;
Macias-Silva et al., 1996). When the Smad2 constructs were
expressed in animal pole explants, the tissue elongated in a
manner characteristic of dorsal mesoderm (not shown)
(Baker and Harland, 1996; Graff et al., 1996; Rosa et al.,
1988; Thomsen et al., 1990). The formation of dorsal
mesoderm was confirmed by molecular analyses, which
demonstrated that all the Smad2 constructs induced the
expression of muscle actin and not the ventral marker
globin, just like wild-type Smad2 (Fig. 1A). Similar results
were obtained with other doses of the Smad2 truncations
(not shown). This is consistent with the prevailing idea that
transcriptional specificity is contained in the MH2 domain,
a region where some key residues for specificity have been
mapped (Chen et al., 1998; Lagna and Hemmati-Brivanlou,
1999). In agreement with previous studies, we found that
the MH1 domain was inhibitory as full-length Smad2 was
less active than forms that lack the MH1 domain (ILT, ETP,
Fig. 1A) (Baker and Harland, 1996; Hata et al., 1997; Liu et
al., 1996; Meersseman et al., 1997; Wu et al., 1997).
We also generated a series of Xenopus Smad1 amino-
erminal truncations and examined their activity in animal
aps (Fig. 1B). As previously reported, full-length Smad1
enerated ventral mesoderm as evidenced by formation of
uid-filled vesicles (not shown) that expressed globin, a
arker of ventral mesoderm, but not the dorsal mesoder-
al marker, muscle actin (Fig. 1B) (Graff et al., 1996;
oodless et al., 1996; Thomsen, 1996). The longest Smad1
utant, QGD, behaved identically to wild-type Smad1 and
nduced expression of globin (Fig. 1B). However, the next
ve truncations, MEE, RSL, YNP, MPH, and YPN, were
nactive based on both morphological (not shown) and
olecular criteria (Fig. 1B). Of note, Western blots with
mad1-specific antibodies demonstrated that all the Smad1
onstructs were expressed to roughly equal levels (not
hown). The two shortest Smad1 constructs, DTP and VAY,
ere active, but in an unanticipated manner. They did not
nduce the formation of ventral mesoderm, but rather
enerated dorsal mesoderm based upon morphology (not
hown) and the expression of muscle actin in the absence of
lobin (Fig. 1B). Microinjection of other doses of the Smad1
onstructs demonstrated identical results (not shown).
hus, the Smad1 MH2 domain functions like wild-type
mad2 rather than Smad1. This suggested a departure from
he conventional view that the MH2 domain functions just
ike the full-length parent Smad.
To elaborate on the surprising idea that the effector MH2
omain does not equate to wild-type activity, we analyzed
he function of truncations of four other Smads: human
mad4, murine Smad5, and Xenopus Smads 10 and 11.
mad5 is most structurally and functionally related to
mad1 with 90% identity at the amino acid level and both
nduce the expression of globin in animal cap assays (Fig.
C) (Graff et al., 1996; Suzuki et al., 1997). The co-Smad,
mad4, has been reported to induce both muscle actin and
lobin (Zhang et al., 1997), although in our studies (n 5 6) it
Copyright © 2001 by Academic Press. All rightnly induced globin (Fig. 1C). Smad10, also known as
Smad4b, is most similar in structure to Smad4 with 63%
equence identity (Howell et al., 1999; LeSueur and Graff,
999; Masuyama et al., 1999). However, in contrast to
mad4, Smad10, similar to other R-Smads, has carboxyl
erminal serines (Howell et al., 1999; LeSueur and Graff,
999; Masuyama et al., 1999). Unlike Smad4, which in-
uces mesodermal fates, Smad10 does not generate meso-
ermal tissues, but rather induces formation of neural
issue that expresses NCAM (Fig. 1C) (LeSueur and Graff,
999). Previous reports suggested that Smad10 could syner-
ize with either Smad1 or Smad2 for the expression of
esodermal genes. However, Smad10 does not induce me-
odermal fates based upon either histology or in situ hy-
ridizations (LeSueur and Graff, 1999). We also isolated a
ew Xenopus Smad, Smad11, which is most structurally
imilar to Smad8 (82% sequence identity), Smad5 (77%
equence identity), and Smad1 (78% sequence identity).
owever, unlike these BMP-restricted Smads that induce
ormation of blood, Smad11 was inactive in animal cap
ssays (Fig. 1C). Structure-function studies with Smad5,
mad10, and Smad11 revealed equivalent results to those
btained with Smad1 (Fig. 1C). For example, truncations of
hese Smads that initiated translation in the linker region
ere inactive (not shown). The MH2 domains of all three of
hese Smads induced expression of muscle actin (Fig. 1C). In
ontrast, the equivalent MH2 construct of Smad4 was
nactive (n 5 4) (Fig. 1C). Equivalent results were obtained
ith other doses of the constructs (not shown). Therefore,
runcated forms of all Smads tested, except the co-Smad,
mad4, that lack the MH1 domain and contain the MH2
omain lose wild-type specificity and generate a response
hat mimics Smad2 (Fig. 1C).
Heterologous MH1 Domains Can Confer Wild-
Type Specificity to MH2 Domains
As many Smads that lack the MH1 domain do not have
wild-type function, the MH1 domain might contain infor-
mation about functional specificity. To assess that, we
generated chimeras that contained the MH1 domain of one
Smad fused to the MH2 of a different Smad (Fig. 2). If the
MH1 domain contained key residues for wild-type specific-
ity, then the chimeras should function like the parent of the
MH1 domain. Alternatively, if the information central to
specificity is located in the MH2 domain, the chimeras
should have the activity of the MH2 parent Smad.
We chose Smad10 for the initial chimeras because, unlike
the other positively acting Smads, Smad1, Smad2, Smad4,
and Smad5, that all generate mesodermal fates, Smad10
forms neural tissue, an ectodermal, rather than mesoder-
mal, derivative (Fig. 1C) (LeSueur and Graff, 1999). That is,
Smad10 has the most distinct functional output of the
various R- and co-Smads. We first generated chimeras of
Smad10 with Smad2 (Fig. 2A). In these constructs, we fused
the MH1 domain of Smad10 to the MH2 domain of Smad2,
termed Smad10/2, and we made the reciprocal construct
s of reproduction in any form reserved.
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117Smad Transcriptional Specificitycontaining the MH1 of Smad2 fused to the MH2 of Smad10,
termed Smad2/10 (Fig. 2A). Then, we microinjected mRNA
encoding the chimeras into Xenopus embryos for functional
FIG. 2. Heterologous Smad MH1 domains can confer wild-type
specificity to MH2 domains. (A) Cartoon of constructs and RT-PCR
results. The MH1 domain of Smad10 was fused to the MH2 domain
of Smad2 (Smad10/2) and vice versa (Smad2/10). Synthetic mRNA
(4 ng) encoding these chimeric constructs or the wild-type parent
Smads were microinjected into Xenopus embryos for functional
analysis. Animal cap assays demonstrated that the chimeras had
similar activity to that observed for the parent of the MH2 domain.
Analysis and the lanes are as described in Fig. 1. (B) Summary of
RT-PCR analysis of animal cap assays performed with various
Smad chimeras. The data are consistent with the idea that the MH2
domain contains specificity but that it requires an MH1 domain to
permit that information to be observed.analysis. In the animal cap assay, the Smad10/2 chimera
Copyright © 2001 by Academic Press. All rightnduced expression of muscle actin, behaving like wild-type
mad2, the parent of the MH2 domain (Fig. 2A). The
eciprocal chimera, Smad2/10, also mimicked the activity
f the MH2 parent, inducing NCAM expression just like
ild-type Smad10 (Fig. 2A). What is notable about the latter
onstruct is that the MH1 domain of Smad2 is normally
resent in a molecule that induces expression of muscle and
he isolated Smad10 MH2 domain also induced muscle.
et, the combination of the two domains did not generate
uscle but rather formed neural tissue. In summary, the
mad2/10 and Smad10/2 chimeras both functioned like the
ild-type parent of the MH2 domain. This suggests that the
resence of an MH1 domain is important for wild-type
ctivity, but that the identity of the MH1 domain is not the
ritical component.
To extend these results, we generated several additional
himeras: 1/10, 10/1, 5/2, 2/5, 1/2, and 2/1. The chimeras
hat were active, 5/2, 1/2, all behaved like the parent of the
H2 domain (Fig. 2B). However, this is also the activity of
he Smad2 MH2. Three chimeras, 10/1, 2/5, and 2/1, did not
ave the activity of a wild-type Smad. That is, they did not
nduce the markers induced by the parent of either the MH1
r MH2 domain. Of note, they also did not induce the
ormation of muscle actin, an activity inherent in the
runcations that lacked the MH1 but contained the MH2
Fig. 2B). So, one plausible explanation for these three cases
s that addition of an MH1 domain was sufficient to
liminate induction of muscle actin but was unable to
ompletely convert it back to wild-type specificity. Trans
oexpression studies lend support to this notion (see below).
lternatively, this lack of function may be due to problems
nherent in chimeric analyses such as protein stability,
lthough Western blots suggested roughly equal levels of
xpression (not shown), or improper folding. Another pos-
ibility is that for some Smads the chimeras cannot behave
ike wild-type. However, the lack of function may also
eflect a difference in potency. In support of that notion, all
f the nonfunctional chimeras contained an MH2 domain
erived from Smads, Smad1 or Smad5, that transduce BMP
ignals; and BMP signaling components are not as active as
ctivin or TGFb signals (Graff et al., 1996; Hemmati-
Brivanlou and Thomsen, 1995; Thomsen et al., 1990;
Thomsen and Melton, 1993). In summary, these data
coupled with the studies on the isolated MH2 domains (Fig.
1) are consistent with the idea that the MH2 domain
contains the specificity and that the MH1 domain can
permit that information to be espoused. What is intriguing
about this notion is that the MH1 domain can be derived
from Smads with specificity distinct from the endogenous
MH1.
To analyze the possibility that incorporation of any
amino acids at the amino terminus is all that is required to
reveal wild-type specificity or to move from expression of
muscle actin to no induction, we generated chimeras of the
MH2 domain of Smad10 with amino acids 1–149 of Gal-4.
We chose this region of Gal-4 because, like Smads, it
contained both a DNA binding and oligomerization do-
s of reproduction in any form reserved.
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118 Fortuno, LeSueur, and Graffmain, was derived from the amino terminus like the Smad
MH1 domain, and was roughly the same length as a Smad
MH1 domain (Ptashne, 1988). The Gal-4/Smad10 construct
behaved like the isolated MH2 domain and induced expres-
sion of muscle actin (not shown). This supports the idea
that the ability to regain wild-type function is not indis-
criminant and might be specific to Smad MH1 domains.
The Smad MH1 Domain Rescues Specificity
in trans
Another way to test whether the effect of the inclusion of
a Smad MH1 domain was specific and required in cis was to
express the MH1 and MH2 domains in trans. Presumably,
outcomes that are observed in trans studies are less likely to
be secondary to changes in protein stability or improper
folding that might affect cis chimeric analyses. When
expressed alone, none of the MH1 domains were active in
the animal cap assay (Fig. 3, not shown). Trans coexpression
of the Smad1 MH1 domain with the Smad1 MH2 domain
changed the activity of the Smad1 carboxyl construct from
the induction of muscle actin back to the expression of
globin, recapitulating wild-type Smad1 function (Fig. 3A).
As a specificity control, we also coexpressed, in trans, the
Smad1 MH1 domain with the Smad2 MH2 domain and this
combination induced the expression of muscle actin just
like wild-type Smad2 or the Smad1/2 chimera. However,
muscle actin induction is also observed when the Smad2
carboxyl construct was expressed alone (Fig. 3A).
We also expressed, in trans, several different combina-
tions of Smad MH1 and MH2 domains and found that, in
large part, the data paralleled that observed with the cis
chimeras (Figs. 2B and 3B). Trans expression of several
different MH1 domains with the MH2 domain of Smad2
generated induction of muscle actin (Fig. 3B). This repro-
duced the effects of wild-type Smad2 and the cis chimeras
that contained the Smad2 MH2 domain (Fig. 2). The
strength of these data is limited as the isolated Smad2 MH2
domain also had the same activity. Coexpression of the
Smad2 MH1 with the Smad1 MH2 eliminated expression of
muscle actin but did not induce the expression of globin.
So, when expressed in trans, the Smad2 MH1 domain was
able to abrogate the illicit activity of the Smad1 MH2
domain but was insufficient to restore wild-type function.
This finding mimicked what we observed with the Smad2/1
cis chimera (Fig. 2B). Although this lack of activity is open
to several possible interpretations, it is consistent with the
idea that the effect might be a specific move from muscle
actin expression toward wild-type function. In support of
this notion, coexpression of the Smad10 MH1 domain with
the Smad1 MH2 domain generated the expression of both
muscle actin and globin (Fig. 3B). This might represent a
partial rescue of wild-type function, which could result
from an inappropriate ratio of expression of the two do-
mains. In summary, the data obtained with the trans
expression support the cis experiments and both studies are
consistent with the ideas that the MH1 and MH2 domains
Copyright © 2001 by Academic Press. All rightnteract, that most Smads can activate a Smad2-like path-
ay, and that certain features of some MH1 domains confer
ild-type specificity.
The Smad MH1 Domain Alters Transcription
Factor Binding to the MH2 Domain
One possible explanation for the findings that the Smad
MH2 domain contains specificity, yet, a Smad MH1 domain
permits wild-type function, is that the MH1 domain might
FIG. 3. The MH1 domain can rescue specifically when expressed
in trans. (A) Schematic of experimental design and RT-PCR results.
Synthetic mRNA encoding either Smad1-N (5 ng), Smad1-C (4 ng),
or Smad2-C (1 ng) were expressed either alone or together in
Xenopus animal caps and RT-PCR analysis was performed as
described in Fig. 1. Smad1 (4 ng) or Smad2 (1 ng) were expressed as
positive controls. (B) Results from trans coexpression of several
different combinations of Smad MH1 and MH2 domains are
summarized.alter the transcription factors that interact with the MH2
s of reproduction in any form reserved.
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119Smad Transcriptional Specificitydomain. The best studied example of a transcription factor
that functions with distinct Smads is FAST-1, a winged-
helix/forkhead domain protein (Chen et al., 1996, 1997a;
Watanabe and Whitman, 1999; Zhou et al., 1998). FAST-1 is
a component of TGF-b and activin signaling, is required for
activin and Smad2-dependent induction of gene expression,
induces the activin/Smad2-specific subset of genes (i.e.
muscle actin), and binds to Smad2 (Chen et al., 1996, 1997a;
Watanabe and Whitman, 1999; Zhou et al., 1998). However,
FAST-1 is not required for BMP/Smad1 signaling, does not
induce the BMP/Smad1-specific subset of genes (i.e., glo-
bin), and does not bind to Smad1 (Chen et al., 1996, 1997a;
Watanabe and Whitman, 1999; Zhou et al., 1998). These
data coupled with the observation that FAST-1 binds to the
Smad2 MH2 domain makes FAST-1 a plausible candidate
for a transcription factor whose interaction with Smad
MH2 domains is regulated by the MH1 domain.
In Xenopus, FAST-1 is required for formation of muscle
(Watanabe and Whitman, 1999). Smad2 also requires
FAST-1 to induce the expression of muscle (Watanabe and
Whitman, 1999). As the Smad1, Smad2, and Smad5 trunca-
tions induced expression of muscle actin (Fig. 1C), it
seemed plausible that FAST-1 might be necessary for that
activity. To determine that, we coexpressed the Smad1,
Smad2, and Smad5 truncations with a dominant negative
form of FAST-1, DN-FAST-1 (Watanabe and Whitman,
1999), and performed animal cap assays. We found that
DN-FAST-1 blocked the induction of muscle actin by all
three constructs (Fig. 4A). Although alternative explana-
tions are plausible, this blockade could be consistent with
the notion that FAST-1 associates with the isolated MH2
domains. To assess this, we microinjected mRNA that
encoded myc-tagged forms of wild-type Smad1 and Smad2
or truncated forms of Smad1 and Smad2 containing the
MH2 domain into embryos with and without GST-FAST-1.
We then performed a GST pull-down and determined
whether the Smads associated with FAST-1 by probing a
Western blot with an antibody (9E10) directed against the
myc epitope. As reported, Smad2 and Smad2 MH2 associ-
ated with FAST-1 while wild-type Smad1 did not (Fig. 4B)
(Chen et al., 1996, 1997a). Of note, Smad1 MH2 also formed
a complex with FAST-1 (Fig. 4B). Therefore, the Smad1
MH1 domain altered both the activity of the Smad1 MH2
domain and the ability of the MH2 domain to interact with
the transcription factor, FAST-1. To further test the ability
of the MH1 domain to alter the binding of the MH2 domain
with FAST-1, we repeated the experiment with the MH1
domain reintroduced in trans. We found that the MH1
blocked the association of the Smad1 MH2 domain with
FAST-1 (Fig. 4C), a result consistent with the inability of
the full-length Smad1 to interact with FAST-1. The Smad2
MH1 domain, which inhibited the ability of Smad1-C to
induce muscle actin (Figs. 2B and 3B), also blocked the
Smad1 MH2 association with FAST-1 (Fig. 4C). Of note, the
MH1 domains from either Smad1 or Smad2 had no signifi-
cant effect on the ability of Smad2 MH2 to induce muscle
actin or to associate with FAST-1 (Figs. 2B, 3B, and 4D).
Copyright © 2001 by Academic Press. All rightNext, we attempted to determine whether the associa-
tion of the truncated Smads with FAST-1, observed in the
GST pull-downs, was direct, by exploiting the yeast two-
hybrid assay. As bait, we made a chimera of FAST-1 with
the Gal4 DNA binding domain. For prey, we fused the
full-length and truncated MH2 domains of Smad1 and
Smad5 and for positive controls, Smad2, to the Gal4 trans-
activation domain. To quantitate the potential interactions,
we employed a liquid culture b-galactosidase assay (Tall et
al., 1999). As reported, Smad2 and Smad2 MH2 directly
interacted with FAST-1 in yeast (Fig. 4E) (Chen et al.,
1997a). In contrast, Smad1 did not directly associate with
FAST-1 (Fig. 4E). However, the truncated Smad1 did di-
rectly associate with FAST-1, albeit relatively weakly (Fig.
4E). Qualitatively similar results hold for Smad5 with low
level binding of full-length Smad5 to FAST-1 coupled with
a marked increase in binding of the truncated Smad5
(Smad5 DTP) to FAST-1 (Fig. 4E). The degree of binding of
Smad5 DTP to FAST-1 approximated that of FAST-1 with
Smad2 or the truncated Smad2 (Fig. 4E). We interpret these
results as suggesting that the MH1 domain inhibits the
direct association of the Smad1 or Smad5 MH2 domain
with FAST-1. The direct interaction of the MH2 domains
with FAST-1 observed in the yeast two-hybrid assay may
not account for all the association observed in the GST
pull-downs (Fig. 4E), as the relative bindings do not com-
pletely correlate. So, there might be an increase in direct
and indirect binding of the MH2 domain to FAST-1 or the
yeast two-hybrid assay is not a perfect measure of the
interaction in Xenopus. Taken together, the FAST-1 data
are consistent with the idea that the Smad MH1 domain
permits the appropriate selection of transcription factors
that associate with the MH2 domain, which may explain
how the MH1 domain permits wild-type specificity.
DISCUSSION
TGF-b superfamily signaling, transduced from the mem-
brane to the nucleus via Smad proteins, is essential for
many critical biological processes (reviewed in Heldin et
al., 1997; Letterio and Roberts, 1998; Massague, 1998;
Whitman, 1998). When TGF-b signaling pathways are al-
ered, human pathophysiological states, including develop-
ental abnormalities and cancers, result (Eppert et al.,
996; Thomas et al., 1996; reviewed in Hata et al., 1998b;
etterio and Roberts, 1998; Massague, 1998; Padgett, 1999).
ne step toward understanding the signaling pathways, and
he diseases that result upon their deregulation, is to
lucidate the structural elements that underlie normal
unction. We have examined the regions of the Smads that
re essential for downstream transcriptional specificity by
xploiting the unique advantages provided by in vivo func-
ional analysis in an organism and tissues in which TGF-b
signaling is endogenously active (Baker and Harland, 1996;
Graff et al., 1996). One benefit of studying Smad structure-
s of reproduction in any form reserved.
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120 Fortuno, LeSueur, and Grafffunction relationships is that the family contains several
members that have a high degree of sequence identity, yet
they transduce distinct and specific signals (Chen et al.,
1998; Graff et al., 1996; Heldin et al., 1997; Hoodless et al.,
1996; Lagna and Hemmati-Brivanlou, 1999; LeSueur and
Graff, 1999; Liu et al., 1996; Suzuki et al., 1997). By
investigating Smad function in a developing embryo, we
were able to monitor several discrete physiological re-
sponses that were easily distinguishable.
FIG. 4. The Smad MH1 domain alters binding of the MH2 doma
(DN-FAST-1) blocks the activity of the MH2 domains of Smad1, Sm
synthetic mRNA encoding Smad2 (1 ng), Smad2ETP (0.5 ng), Sma
At stage 28, RNA was harvested and RT-PCR analysis performed
mRNA encoding myc-Smad1 (5 ng), myc-Smad2 (5 ng), myc-Sma
Xenopus embryos with or without GST-FAST-1 (6 ng). At stage
glutathione beads. The potential presence of Smads that associated
antibody against the myc-epitope. Protein expression was analyzed
the myc-epitope (Smads) or the GST (FAST-1). Of note, full-length
lacking the MH1 domain, did. (C) Trans expression of MH1 dom
encoding myc-Smad1 (15 ng), myc-Smad1 DTP (15 ng), and myc-Sm
injected in the presence or absence of GST-FAST-1 (20 ng). After 60
MH1 domains do not alter Smad2 MH2 domain binding to FAST-
Smad1-N (20 ng) or Smad2-N (20 ng) were microinjected and pull-d
FAST-1. Full-length or truncated Smads were analyzed for a direct
of binding was assessed by a quantitative liquid culture b-galactosGiven the importance of TGF-b signaling, the Smads
Copyright © 2001 by Academic Press. All righthave been intensively investigated and several concepts
have emerged about the regions that control wild-type
activity (Heldin et al., 1997; Massague, 1998). The Smad
MH1 domain is thought to inhibit the MH2 effector func-
tion. The MH2 domain has many important functions
including Smad oligomerization; binding to sequence spe-
cific transcription factors such as FAST-1; transcriptional
transactivation; and transcriptional specificity (Baker and
Harland, 1996; Chen et al., 1996, 1997a; Lagna et al., 1996;
the transcription factor FAST-1. (A) Dominant-negative FAST-1
, and Smad5. Animal poles of one-cell embryos were injected with
P (4 ng), or Smad5DTP (4 ng) with or without DN-FAST-1 (6 ng).
scribed in Fig. 1. (B) Smad MH2 domains associate with FAST-1.
TP (5 ng), and myc-Smad2ETP (3 ng) were injected into one-cell
embryos were lysed and the GST-FAST-1 was precipitated with
FAST-1 in the pull-down was assessed by Western blots with an
Western blots of the lysates probed with antibodies against either
d1 did not interact with FAST-1, while the truncated Smad1 DTP,
abrogates the association of Smad1 MH2 with FAST-1. mRNA
DTP (15 ng) with either Smad1-N (20 ng) or Smad2-N (20 ng) were
lls were lysed and the pull-down was performed as in (B). (D) Smad
yc-Smad2 (15 ng), myc Smad2 ETP (15 ng) with or without either
were performed as in (C). (E) Smad MH2 domains bind directly to
iation with FAST-1 in a yeast two-hybrid assay. Relative strength
assay (Tall et al., 1999).in to
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121Smad Transcriptional Specificity1997). The studies presented here support these concepts
and extend them.
The idea that the Smad MH1 domain is inhibitory and
that the MH2 domain has wild-type specificity is based, in
large part, on previous studies performed with Smad2
(Baker and Harland, 1996; Liu et al., 1996). We examined
Smad2 structure-function relationships by analyzing the
activity of a series of truncated forms of Smad2 in Xenopus
embryos. Our data were consistent with previous results
and showed that the Smad2 MH1 domain inhibited effector
function and that the Smad2 MH2 domain had wild-type
specificity, scored by induction of muscle actin. Compa-
rable studies performed with equivalently truncated forms
of Smad1 revealed surprisingly different results. Animal
caps microinjected with wild-type Smad1 expressed globin
and not muscle actin. The MH2 domain of Smad1 did not
behave like wild-type Smad1 but rather induced formation
of muscle, mimicking the function of Smad2. We also
analyzed the function of the isolated MH2 domains of
several other Smads, Smad5, Smad10, Smad11, and Smad4,
and the results supported the Smad1 data as the MH2
domains of all these Smads lost wild-type specificity and,
except for the co-Smad, Smad4, induced formation of
muscle. These data suggest that this phenomenon is gener-
alizable and that the ground state of many Smad MH2
domains is to function like wild-type Smad2. In sum,
wild-type Smad specificity is lost, except for Smad2, when
the MH1 domain is removed from the effector MH2 do-
main. This suggested that the MH1 domain plays a role in
transcriptional specificity.
One possible explanation for these findings was that the
individual MH1 domains contained specific information
about transcriptional activation. To address that, we made
chimeric clones that contained the MH1 domain of one
Smad with an MH2 domain of another Smad. A few
constructs were inactive, expressing neither muscle actin,
an inherent function of their MH2 domain, nor their
specific wild-type effector function. This may represent a
partial rescue toward wild-type activity. However, the ma-
jority of the chimeras had the wild-type specificity of the
MH2 parent. The ability of an MH1 domain to restore
wild-type specificity to the MH2 domain was also observed
when the two domains were expressed in trans. Consistent
with this, bacterially expressed MH1 and MH2 proteins
interact specifically and directly in vitro (Hata et al., 1997).
Taken together, these findings support previous reports that
Smad specificity is contained in the MH2 domain (Chen et
al., 1998; Lagna and Hemmati-Brivanlou, 1999). We have
extended this concept and demonstrated that wild-type
activity, except for Smad2, also requires an MH1 domain.
What is also notable about these findings is that the mere
presence of an MH1 domain can be more important than its
identity. In summary, these studies have revealed a new
and important role for the Smad MH1 domain in down-
stream transcriptional specificity.
The presence or absence of the Smad MH1 domain
altered the pattern of gene expression in response to Smad1,
Copyright © 2001 by Academic Press. All rightmad4, Smad5, Smad10, and Smad11. This suggested that
he MH1 domain might also change the identity of the
ranscription factors that bind the MH2 domain. A likely
andidate for such a transcription factor was FAST-1 (Chen
t al., 1996, 1997a). For, Smad2 and FAST-1 induce the
xpression of muscle actin, Smad2 binds to FAST-1, and
mad2 requires FAST-1 for function (Chen et al., 1996,
997a; Watanabe and Whitman, 1999; Zhou et al., 1998). In
ontrast, Smad1 has a different effector function than
AST-1 and Smad1 neither binds to FAST-1 nor requires
AST-1 for function (Chen et al., 1996, 1997a; Graff et al.,
996; Hoodless et al., 1996; Watanabe and Whitman, 1999;
hou et al., 1998). Notably, however, the Smad1 MH2
omain induced muscle actin expression, required FAST-1
or this function, and associated with FAST-1 in both GST
ull-down experiments and yeast two-hybrid assays. There-
ore, the MH1 domain may confer transcriptional specific-
ty by altering the selection of sequence-specific transcrip-
ion factors with which the Smads associate.
In summary, we find that the MH2 domains of pathway
estricted Smads contain effector function. But, rather than
etaining wild-type activity, all the MH2 domains function
n a similar manner, inducing the expression of muscle
ctin, a Smad2-like effect. To espouse wild-type function,
he Smads, except for Smad2, must contain an MH1 do-
ain. Of note, heterologous MH1 domains are able to
eveal wild-type activity. This suggests that wild-type func-
ion is inherent in the MH2 domain but requires the
resence of an MH1 domain. In turn, the MH1 domain
lters the interaction of the MH2 with transcription factors
nd hence downstream targets. This is likely due to an
lteration in the tertiary structure of the Smads. For ex-
mple, the inclusion of the MH1 domain might generate a
ew interface for transcription factor binding or might
hange the conformation of the MH2 domain. Further
tructural information of the MH2 domain in the presence
nd absence of the MH1 domain might be informative in
his regard.
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